LENZ Therapeutics Stock Soars on US Launch of VIZZ Eye Drops
With a potential market of 128 million in the U.S., analysts see blockbuster potential for the new presbyopia treatment.
Shares of LENZ Therapeutics (NASDAQ: LENZ) surged more than 20% after the company announced the U.S. commercial launch of VIZZ, its new eye drop for the treatment of presbyopia. The launch marks a pivotal transition for the company, moving from a clinical-stage entity to a commercial enterprise with a product targeting a massive untapped market.
VIZZ is the for treating presbyopia, the age-related loss of near vision. The treatment works by creating a 'pinhole effect' through pupil constriction, which improves near vision for up to 10 hours without the common side effect of blurring distance vision. Clinical trial data was impressive, with 93% of participants achieving 20/40 or better near vision within just 30 minutes.
The market opportunity for VIZZ is substantial. An estimated , a condition that impacts nearly everyone over the age of 45. The global market for presbyopia treatments is projected to expand rapidly, potentially reaching over $29 billion by 2032, highlighting the significant commercial potential for an effective and long-lasting treatment.
Wall Street has reacted positively to the launch, with analysts seeing a clear path to market adoption. Following the news, , maintaining a 'Buy' rating. Others, including analysts at William Blair, have suggested the drug's 'best-in-class profile' could lead to a more successful rollout than previous treatments in the space, even hinting at future blockbuster sales potential. Initial feedback from eye care professionals has reportedly been 'extremely positive'.
With the launch underway, investor focus now shifts from regulatory milestones to commercial execution. The company is distributing professional samples nationwide, with consumer shipments expected to begin in October. While the FDA label includes a warning for retinal detachment, a known risk for this class of drugs, analysts do not expect it to significantly hinder adoption. The key for LENZ Therapeutics will be to successfully navigate the challenges of physician adoption and build strong early sales momentum.